Market Place
Sourcing Support
Henlius & SVAX Forge Strategic Partnership in the MENAT Market
08 Nov 2024 //
PR NEWSWIRE
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY
21 Sep 2024 //
PR NEWSWIRE
Henlius Xgeva® Prolia® Biosimilar: Ema Filings With Organon Validated
24 May 2024 //
BUSINESSWIRE
Henlius Releases 2023 ESG Report Focused on Sustainability
17 Apr 2024 //
PR NEWSWIRE
Henlius Forecasts Profit in 2023: Achieving first full year of profitability
04 Mar 2024 //
PR NEWSWIRE
The NDA for New Indication of Henlius Serplulimab Accepted by the NMPA
12 Dec 2023 //
PR NEWSWIRE
Henlius Reported Financial Results for the First Three Quarters of 2023
15 Nov 2023 //
PR NEWSWIRE
Henlius Deepens Collaboration with Intas to bring Serplulimab to Europe & India
27 Oct 2023 //
PR NEWSWIRE
Henlius` Novel Anti-PD-1 mAb HANSIZHUANG Approved for ESCC
22 Sep 2023 //
PR NEWSWIRE
Henlius Expands Collaboration with KGbio
12 Sep 2023 //
PR NEWSWIRE
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues
25 Aug 2023 //
PR NEWSWIRE
Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged
16 Apr 2023 //
PR NEWSWIRE
Henlius 2022 Annual Results
31 Mar 2023 //
PR NEWSWIRE
EMA Validates Marketing Authorization Application for Henlius` HANSIZHUANG
23 Mar 2023 //
PR NEWSWIRE
Henlius` Novel Anti-PD-1 mAb HANSIZHUANG Approved for ES-SCLC
17 Jan 2023 //
PR NEWSWIRE
Fosun Pharma and Henlius Entered into an Agreement for Serplulimab in the US
07 Jan 2023 //
PR NEWSWIRE
Henlius & Fosun Pharma Entered into License Agreement for HANSIZHUANG in the US
28 Dec 2022 //
PRESS RELEASE
Henlius Received IND Approval from US FDA for HLX07 in CSCC patients
29 Sep 2022 //
PRESS RELEASE
PII Study of the PD-1 Inhibitor Serplulimab & Bevacizumab HANBEITAI in Patients
09 Sep 2022 //
HENLIUS
Henlius H1`22 Results: Sharpen all-round edge, advance in evolution to Biopharma
18 Aug 2022 //
PRNEWSWIRE
Palleon and Henlius Enter into Strategic Collaboration for Sialidase Therapies
28 Jun 2022 //
BUSINESSWIRE
NMPA Accepts NDA of Henlius` Serplulimab for 1L SCLC
11 Apr 2022 //
PRNEWSWIRE
Henlius` Serplulimab Granted ODD in U.S. for SCLC
07 Apr 2022 //
PRNEWSWIRE
Henlius` 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by NMPA
03 Dec 2021 //
ASIAONE
Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial
29 Nov 2021 //
PRNEWSWIRE
Henlius to publish 4 oral presentations of two commercial products: CSCO 2021
19 Sep 2021 //
PRNEWSWIRE
The Chinese NMPA has accepted Henlius` application for Serplulimab
17 Sep 2021 //
PRNEWSWIRE
Henlius reports half-year (H1) 2021 results, outlines remarkable growth
18 Aug 2021 //
PRNEWSWIRE
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the of MSI-H
29 Mar 2021 //
BIOSPACE
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10
26 Mar 2021 //
PRNEWSWIRE
Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies
15 Jan 2021 //
PRESS RELEASE
The IND Application Of Henlius Daratumumab Biosimilar Accepted By NMPA
14 Jan 2021 //
BIOSIMILARDEVELOPMENT
Henlius Adalimumab Biosimilar Approved by NMPA
08 Dec 2020 //
PRNEWSWIRE
Essex & Henlius Entered into a Global Co-DevP and Exclusive License Agreement
16 Oct 2020 //
ESSEXBIO
Mr. Wenjie Zhang appointed as the CEO of Henlius to keep innovating
30 Sep 2020 //
PRESS RELEASE
Shanghai Henlius Biotech’s trastuzumab biosimilar HLX02 gets China NMPA approval
18 Aug 2020 //
PHARMABIZ
Henlius and Accord Healthcare Receive EMA Approval for Zercepac®
29 Jul 2020 //
PRNEWSWIRE
Henlius y Accord reciben opinión positiva de CHMP para HLX02 (Trastuzumab)
01 Jun 2020 //
PRNEWSWIRE
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
23 Apr 2020 //
PR NEWSWIR
